跳到主要內容
Quest Diagnostics Home.

致力於幫助您識別心血管風險

An estimated 80% of cardiovascular disease (CVD), including heart disease and stroke, is preventable. However, CVD remains the leading cause of death and the most expensive disease, costing nearly $1 billion a day1.

\r\n

Guidelines are evolving to implement new kinds of cardiovascular diagnostic and prognostic testing services aimed at prevention and early intervention.

\r\n

Quest Diagnostics is at the forefront, committed to providing innovative solutions that provide additional and complementary insight to help identify those most at risk.

\r\n","@type":"corporate/components/text"}}" id="text-d58f9e4e2e" class="cmp-text">

估計的80%的心血管疾病(CVD),包括心髒病和中風,可預防。然而,CVD仍然是死亡的主要原因和最昂貴的疾病,每天占10億美元1

準則正在發展,以實施旨在預防和早期幹預的新型心血管診斷和預後測試服務。

Quest Diagnostics位於最前沿,致力於提供創新的解決方案,提供額外的和互補的洞察力,以幫助確定最大的風險。

Going beyond standard lipid panels to assess lipoprotein, apolipoprotein, inflammatory, metabolic, and genetic risk factors may provide deeper insights into the residual risk of your patients.

\r\n

Advanced biomarkers have been shown to help identify residual risk and have been adopted by several practice guidelines and professional societies.2,3 With deeper insights, you can take further action to help reduce your patients’ risk for adverse cardiovascular events. 

\r\n","@type":"corporate/components/text"}}" id="text-f24e71983b" class="cmp-text">

超越標準脂質麵板以評估脂蛋白,載脂蛋白,炎症,代謝和遺傳危險因素可能會對您患者的殘餘風險提供更深入的見解。

已顯示先進的生物標誌物有助於識別剩餘風險,並通過幾種實踐指南和專業社會采用。2,3隨著深度洞察力,您可以采取進一步的行動來幫助減少患者對不良心血管事件的風險。

Nearly 50% of all heart attacks and strokes occur in patients with “normal” cholesterol levels. Recent evidence goes beyond lipids to suggest that inflammation within the artery wall is the primary contributor to this residual risk for heart attack and stroke. Inflammation contributes to both vulnerable plaque formation and to plaque rupture.4

\r\n

The beginnings of CVD are rooted in injury to the arterial wall. Risk factors like smoking, hypertension, and diabetes injure the arterial wall, making it more susceptible to penetration and accumulation of excess lipids.

\r\n

The inflammatory response to injury contributes to the progression of plaque development and is a key factor in the formation of vulnerable plaque and plaque rupture, which may cause a heart attack or stroke. 

\r\n","@type":"corporate/components/text"}}" id="text-c5232f1d50" class="cmp-text">

近50%的心髒病發作和中風患者發生“正常”膽固醇水平。最近的證據超越了脂質,表明動脈牆內的炎症是心髒病發作和中風的這種殘留風險的主要因素。炎症有助於脆弱的斑塊形成和斑塊破裂。4.

CVD的開始根植於動脈壁的傷害。危險因素等吸煙,高血壓和糖尿病損傷動脈牆,使其更容易受到過度脂質的滲透和積累。

對損傷的炎症反應有助於斑塊發展的進展,是脆弱斑塊和斑塊破裂形成的關鍵因素,可能導致心髒病發作或中風。

Patients who have metabolic syndrome are at higher risk of multiple chronic conditions, including diabetes, coronary heart disease, and cancer, as well as stroke. Metabolic syndrome has become increasingly common: its prevalence has risen in every sociodemographic group, and today it is estimated that more than a third of adults in the United States have metabolic risk.5

\r\n","@type":"corporate/components/text"}}" id="text-b7bf5e4364" class="cmp-text">

具有代謝綜合征的患者具有較高的慢性病症的風險較高,包括糖尿病,冠心病和癌症以及中風。代謝綜合征變得越來越普遍:它的普遍存在率在每個社會階段群體中程度上升,今天據估計,美國超過三分之一的成年人具有代謝風險。5.

The recently updated ACCF/AHA guidelines for the management of heart failure recommend BNP or NT-proBNP biomarker testing followed by early intervention as an aid for prevention. Quest offers advanced biomarker testing to help prevent heart failure in your at-risk patients.

\r\n","@type":"corporate/components/text"}}" id="text-1f62124d38" class="cmp-text">

最近更新的ACCF / AHA用於管理心力衰竭的準則推薦BNP或NT-ProbnP生物標誌物測試,然後提前幹預作為預防援助。任務提供先進的生物標誌物測試,以幫助防止患有風險患者的心力衰竭。

In many patients, the risk of CVD may be attributed to nonlipid factors, including genetic polymorphisms and mutations. Quest offers cardiogenetic testing to aid in early diagnosis and earlier treatment for affected patients as well as family members.

\r\n","@type":"corporate/components/text"}}" id="text-94ccfb5997" class="cmp-text">

在許多患者中,CVD的風險可能歸因於非脂質因子,包括遺傳多態性和突變。任務提供型心肌試驗,幫助受影響患者的早期診斷和早期治療以及家庭成員。

定義慢性病條件:一種預防的心肌疾病方法

With more people at risk for cardiovascular disease than ever before, the Quest Cardiometabolic Center of Excellence™ at Cleveland HeartLab® is advancing a prevention-focused approach for heart disease and associated metabolic conditions.

\r\n
    \r\n
  • Cardiovascular disease is the leading cause of death for individuals who have T2DM,6 stage 4-5 CKD,2 and NAFLD.3
  • \r\n
  • Those who have T2DM have a 2 to 3 times higher risk of fatal coronary heart disease.7
  • \r\n
  • Nearly 40% of persons who have diabetes and more than 30% of those who have hypertension also have CKD.8 The leading causes of end-stage renal disease are diabetes and hypertension.9
  • \r\n
  • More than 75% of those who have T2DM have NAFLD.10
  • \r\n
\r\n","@type":"corporate/components/text"}}" id="text-4192003eb2" class="cmp-text">

憑借以前比以往任何時候都有更多人心血管疾病風險,Quest Cardifometabolic卓越中心在克利夫蘭Heartlab®中推進了一種預防心髒病和相關的代謝條件的方法。

  • 心血管疾病是具有T2DM的個人死亡的主要原因,6.階段4-5 CKD,2和nafld。3.
  • 那些具有T2DM的人具有致命冠心病風險較高的2%至3倍。7.
  • 近40%的患有糖尿病和超過30%的高血壓的人也有CKD。8.末期腎病的主要原因是糖尿病和高血壓。9.
  • 超過75%的人有T2DM有NAFLD。10.
Cardiovascular disease (CVD) is strongly associated with type 2 diabetes (T2DM), chronic kidney disease (CKD), and nonalcoholic fatty liver disease (NAFLD). Through significant investments in novel technology, the Cleveland HeartLab® is fostering innovation to detect these conditions in their early stages, providing the opportunity for stage-targeted intervention and improved clinical outcomes.

\r\n","@type":"corporate/components/text"}}" id="text-828eb0760e" class="cmp-text">

心血管疾病(CVD)與2型糖尿病(T2DM),慢性腎病(CKD)和非酒精性脂肪肝病(NAFLD)強烈相關。通過對新技術的重大投資,克利夫蘭Heartlab®正在促進創新,以檢測其早期階段的這些條件,為階段目標幹預提供機會和改善的臨床結果。

全麵的測試範圍

The power of Quest Cardiometabolic Center of Excellence™ at Cleveland HeartLab®
\r\n\r\n","@type":"corporate/components/text"}}" id="text-6c782ab53a" class="cmp-text">

Quest Cardiometabolic Cents卓越中心的力量在克利夫蘭的心髒下®

此信息僅供參與信息,並非作為醫療建議。醫生的考試選擇和解釋,診斷和患者管理決策應基於他/她的教育,臨床專業知識和患者的評估。

參考

  1. 美國心髒協會。CDC預防計劃。2018年5月18日更新。在2021年6月25日訪問。https://www.heart.org/en/get-involded/adocate/federal-priorities/cdc-prevention-programs.
  2. 國家膽固醇教育小組。國家膽固醇教育計劃(NCEP)專家小組的第三次報告在成人中檢測,評估和治療高血膽固醇(成人治療小組III)的最終報告循環2002; 106(25):3143-3421。
  3. 戴維森MH,Corson Ma,Alberts MJ,等。共識組建議將脂蛋白相關的磷脂酶A2測試摻入心血管疾病風險評估指南。AM Cardiol.。2008; 101(12A):51F-57F。DOI:10.1016 / J.AMJCARD.2008.04.019
  4. Sachdeva A,Cannon CP,Deedwania PC等。患有冠狀動脈疾病的患者的脂質水平:分析了136,905名住院治療準則。我的心J.。2009; 157(1):111-117。DOI:10.1016 / J.AHJ.2008.08.010
  5. Moore JX,Chaudhary N,Akinyemiju T.在1988 - 2012年,國家健康和營養考試調查中的種族/種族和性別的代謝綜合征普遍存在。上一慢性病。2017; 14:E24。DOI:10.5888 / PCD14.160287
  6. Lamarche B,Tchernof A,Moorjani S等人。小,致密的低密度脂蛋白顆粒作為男性缺血性心髒病風險的預測因子。Québec心血管研究的前瞻性結果。循環。1997年; 95(1):69-75。
  7. 狐狸cs,sullivan l,d'agostino r等。糖尿病持續時間對冠心病死亡率的顯著影響。糖尿病護理。2004; 27(3):704-708。DOI:10.2337 / DIACARE.27.3.704
  8. Penn Ms,Klemes Ab。識別和記錄心血管風險減輕措施的多馬思。未來的心肺。2013; 9(4):497-506。DOI:10.2217 / FCA.13.27
  9. Ikonomidis I,Mihalakeas Ca,lekakis j等。心血管風險預測中的多點方法。分析標記。2009; 26(5-6):273-285。DOI:10.3233 / DMA-2009-0633
  10. Richard J,Lingvay I.肝髒脂肪變性和2型糖尿病:當前和未來的治療考慮。專家Rev Cardiovasc Ther。2011年3月;9(3):321-328。DOI:10.1586 / ERC.11.15

在Covid-19健康危機期間,比以往任何時候都更快速行動和信任信息。

找出正在發生的事情

了解更多
Baidu
map